**Supplemental Digital Content 2. Antimicrobial Activity of Ceftolozane/tazobactam and Meropenem Tested Against Key Pathogen Baseline Isolates**

|  |  |  |
| --- | --- | --- |
|  | **Ceftolozane/tazobactam** | **Meropenem** |
|  | **MIC50****(µg/mL)** | **MIC90****(µg/mL)** | **MIC range****(µg/mL)** | **MIC50****(µg/mL)** | **MIC90****(µg/mL)** | **MIC range****(µg/mL)** |
| **Enterobacterales (102)** | 0.25 | 0.5 | 0.06-4.0a | ≤0.06 | ≤0.06 | <0.06-4.0b |
|  ***E. coli* (80)** | 0.12 | 0.25 | 0.06-2.0 | ≤0.06 | ≤0.06 | ≤0.06-≤0.06 |
|  ***K. pneumoniae* (9)** | 0.5 | -- | 0.12-2.0 | ≤0.06 | -- | ≤0.06-4.0 |
| ***P. aeruginosa* (8)** | 0.5 | -- | 0.5-1.0 | 0.25 | -- | ≤0.06->8.0c |

MIC, minimum inhibitory concentration; MIC50, MIC value at which 50% of the isolates are susceptible; MIC90, MIC value at which 90% of the isolates are susceptible.

--, Data not available.

aAll Enterobacterales fell within the 0.06-2.0 µg/mL range except for 1 *Serratia marcescens* isolate.

bAll isolates except for 1 each of *E. coli* and *K. pneumoniae* fell within the 0.06-1 µg/mL range.

cAll except for 1 *P. aeruginosa* isolate fell between 0.06-2.0 µg/mL.